Strahlenther Onkol (2018) 194:225–234 https://doi.org/10.1007/s00066-017-1235-5 ORIGINAL ARTICLE A retrospective single institution analysis 1 1 1 1,2 3,4,5 Indrawati Hadi · Olarn Roengvoraphoj · Maximilian Niyazi · Falk Roeder · Ulrich Schüller · 1,6 1 Claus Belka · Silke Birgit Nachbichler Received: 31 July 2017 / Accepted: 26 October 2017 / Published online: 16 November 2017 © Springer-Verlag GmbH Deutschland 2017 Abstract tients. The most common side effects were hematologi- Purpose Adult medulloblastoma is a rare disease treated cal toxicities. Median overall survival (OS) has not been according to the current pediatric treatment guidelines. This reached after a median follow-up of 92 months. Estimated retrospective analysis investigated the clinical outcomes and 5- and 10-year OS was 89 and 80%, respectively. Estimated prognostic factors of adult medulloblastoma patients, who 5- and 10-year progression-free survival (PFS) was 89 and received multimodal therapy at our institution. 81%, respectively. In univariate analysis, a shorter interval Methods Treatment charts of all patients over the age of between tumor resection and end of irradiation was signif- 15 years of age with de novo medulloblastoma, who had icantly associated with improved OS and PFS, anaplastic been treated at our institution between 2001 and 2014, histology with worse
Strahlentherapie und Onkologie – Springer Journals
Published: Nov 16, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera